Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
32 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth of tumor cells and blood vessels the tumor needs to survive. Dabrafenib is an enzyme inhibitor that binds to and inhibits the activity of a protein called B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. Trametinib is also an enzyme inhibitor. It binds to and inhibits the activity of proteins called MEK 1 and 2, which play a key role in activating pathways that regulate cell growth. This may inhibit the growth of tumor cells mediated by these pathways. The usual approach for patients with thyroid cancer is targeted therapy with dabrafenib and trametinib. This trial may help researchers decide which treatment option (cabozantinib alone or dabrafenib in combination with trametinib) is safer and/or more effective in treating patients with refractory BRAF V600E-mutated differentiated thyroid cancer.
Sponsor: ECOG-ACRIN Cancer Research Group
You may qualify if…
- ✓ Patient must be ≥ 18 years of age
- ✓ Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- ✓ Patient must have differentiated thyroid cancer (DTC) with BRAF V600E mutation as determined by local testing, including the following subtypes (Note: results of a previous biopsy will be accepted):
- ✓ Papillary thyroid carcinoma including histological variants of papillary thyroid carcinoma (PTC) such as follicular variant, tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin-like, trabecular, tumor with nodular fasciitis-like stroma, Hürthle cell variant of papillary carcinoma, poorly differentiated.
- ✓ Follicular thyroid carcinoma including histological variants of follicular thyroid carcinoma (FTC) such as Hürthle cell, clear cell, insular, and poorly differentiated
- ✓ Patient must have been previously treated with or deemed ineligible for treatment with Iodine-131 for DTC, and must be receiving thyroxine suppression therapy
- ✓ Patient must have had prior treatment with at least one of the following vascular endothelial growth factor receptors (VEGFR)-targeting tyrosine kinase inhibitor (TKI) agents for DTC: lenvatinib or sorafenib.
- ✓ NOTE: Up to two prior VEGFR-targeting TKI agents are allowed including, but not limited to lenvatinib and sorafenib
Where it's recruiting
Anchorage · Fairbanks
Fort Smith · Little Rock
Burbank · Irvine · Napa · Orange …
Aurora · Highlands Ranch
Derby · Fairfield · Glastonbury · Greenwich …
Fort Lauderdale · Jacksonville
Atlanta
Boise · Caldwell · Coeur d'Alene · Emmett …
Alton · Aurora · Barrington · Centralia …
Crown Point
Ankeny · Bettendorf · Carroll · Cedar Rapids …
Garden City · Great Bend · Pittsburg
Source: ClinicalTrials.gov · NCT06475989 · last updated 2026-11-16